✦ LIBER ✦

Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint

✍ Scribed by M.W. Konstan; J.S. Wagener; A. Yegin; S.J. Millar; D.J. Pasta; D.R. VanDevanter

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Design and powering of cystic fibrosis c

✍ D.R. VanDevanter; A. Yegin; W.J. Morgan; S.J. Millar; D.J. Pasta; M.W. Konstan 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 288 KB

Sample size estimation for CF clinical t

✍ D.R. VanDevanter; M.W. Konstan 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 60 KB

PND67 A Mixed-Effects Piecewise Linear M

✍ D.J. Pasta; S.J. Millar; L. Rasouliyan 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB